Can adagrasib prolong survival?

Adagrasib is a specific inhibitor targeting KRAS G12C mutation. It is an important innovative drug in the current field of precision tumor treatment. KRAS mutation, especially the G12C site, is one of the high-frequency oncogenic mutations found in various tumors such as non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). In the past, due to the lack of druggability of the KRAS protein structure, it was long regarded as "untargetable". It was not until the advent of KRAS G12C inhibitors represented by adagrasib in recent years that this situation changed. Adagrasiib can covalently bind to specific sites on the KRAS G12C mutant protein and inhibit its active state, thereby blocking the RAS/MAPK signaling pathway, slowing the growth of cancer cells and inducing apoptosis.

From the perspective of therapeutic effect, adagrasib has shown positive effects in delaying disease progression, stabilizing tumor burden, and improving progression-free survival, especially in patients who have failed previous standard therapies. Although specific survival data vary from person to person and are affected by multiple factors such as tumor type, mutation background, and combination treatment methods, the accumulated treatment experience shows that adagrasib can significantly prolong the survival time of patients in the advanced stages of the disease, especially those with advanced lung cancer carrying KRAS G12C mutations.

It is worth noting that early use of adagrasib may lead to a better treatment window. With the deepening of more clinical studies, the application of this drug in first-line treatment is also being actively explored, and its role in prolonging overall survival may be more significant in the future. Therefore, adagrasib is regarded as a clinically significant "survival extension regimen" in the field of KRAS targeted therapy, and is especially suitable for patient groups who are resistant to traditional treatments.

Reference materials：https://www.krazati.com/